biomarin.comBioMarin Pharmaceutical Inc.

Skip to main navigation Skip to main content Skip to Footer Clinical Trials Contact Us Careers -- Home Our Motivation Patient Stories Bailey Kendra Sheri Matty Diseases & Conditions PKU CLN2 Disease MPS VI MPS IVA MPS I Patient & Community Support Trees of Life RARE Scholars In the Hemophilia Community Patient Advocacy BioMarin RareConnections™ Grants & Donations Resource Library Patient Organizations Professional Organizations Our Science Our Approach Technical Expertise Indication Expansion Franchise Building Our Scientists Our Publications Funding & Support Independent Medical Education Independent Research Grants & Donations Publication Data Request Our Treatments Our Products PALYNZIQ ® (pegvaliase-pqpz) Injection for PKU Brineura ® (cerliponase alfa) for CLN2 Disease Vimizim ® (elosulfase alfa) for Morquio A Syndrome (MPS IVA) Kuvan ® (sapropterin dihydrochloride) for PKU Aldurazyme ® (laronidase) for MPS I Naglazyme ® (galsulfase) for MPS VI Our Pipeline Valoctocogene Roxaparvovec for Severe Hemophilia A Vosoritide for Achondroplasia BMN 307 for Phenylketonuria (PKU) BMN 331 for Hereditary Angioedema (HAE) Compassionate Use Policy Our Company About Us Our History Manufacturing Excellence Message from Chairman and CEO Global Compliance & Ethics Corporate Social Responsibility Diversity, Equity & Inclusion Environmental Health, Safety and Sustainability (EHS&S) Leadership Team Jean-Jacques Bienaimé Henry J. Fuchs, M.D. Jeff Ajer G. Eric Davis C. Greg Guyer, Ph.D. Brian R. Mueller Lon Cardon, Ph.D. Philip Lo Scalzo Amy Wireman Brinda Balakrishnan, M.D., Ph.D. Board of Directors Grants & Donations Investors & Media Press Releases Events Governance Management Board of Directors Committee Composition Contact the Board SEC Filings Financials 2021 2020 2019 2018 2017 Annual Reports Stock Info Historical Data Resources FAQs Contact Us Email Alerts Search our website Close Our Motivation Patient Stories Diseases & Conditions Patient & Community Support Resource Library Our Science Our Approach Our Scientists Our Publications Funding & Support Our Treatments Our Products Our Pipeline Compassionate Use Policy Our Company About Us Corporate Social Responsibility Leadership Team Board of Directors Grants & Donations Investors & Media Press Releases Events Governance SEC Filings Financials Stock Info Resources Privacy Policy Terms of Use LinkedIn Facebook Site Map Instagram Supplier Information YouTube Glossary © 2021 BioMarin. All rights reserved. Allen Institute & BioMarin Team Up to Explore Gene Therapies for Rare Brain Diseases Learn More  ⌃ -- Scientific discovery driven by genetic diversity Learn more about our approach to research & development Learn More ⌃ CAREERS AT BIOMARIN Our focus on rare disease gives us the rare opportunity to truly impact lives. Learn More about careers with BioMarin ⌃ OUR MOTIVATION We are inspired and driven everyday by stories like Sheri’s. Learn More about Sheri ⌃ Patient & Community Support Treatment is only the beginning. We are committed to the communities we treat beyond the therapies we develop. Learn More about our patient support ⌃ OUR PIPELINE We take on the biggest challenges in rare disease. Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address. View Now ⌃ News View All News and press releases ⌃ May 27, 2021 BioMarin to Participate in Two Upcoming Virtual Investor Conferences May 24, 2021 European Medicines Agency Grants BioMarin’s Request for Accelerated Assessment of Valoctocogene Roxaparvovec for Treatment of Severe Hemophilia A May 19, 2021 BioMarin Provides Highlights of 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec with the Longest Duration of Clinical Experience for a Gene Therapy in Hemophilia A May 18, 2021 BioMarin to Participate in Two Upcoming Virtual Investor Conferences May 12, 2021 BioMarin Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting May 3, 2021 BioMarin to Participate in Two Upcoming Virtual Investor Conferences April 29, 2021 BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates April 28, 2021 Allen Institute and BioMarin Team Up To Develop Gene Therapies For Rare Brain Diseases Home Navigate Our Motivation Our Science Our Treatments Our Company Investors & Media About Our History Our Products Our Pipeline Leadership Team Board of Directors Diversity, Equity & Inclusion Contact Global Contact Information Our Locations Report a Product Complaint Report Adverse Event Publication Data Request Funding & Support Connect Careers LinkedIn Facebook Instagram YouTube Privacy Policy Terms of Use Site Map Supplier Information Slavery Act Statement Glossary Contact Us © 2021 BioMarin. All rights reserved. This website uses cookies to improve website functionality. You may delete or block cookies by accessing your preferences. For more information, please see our Privacy Policy and Terms and Conditions . By using this website, you consent to our use of cookies. Accept...